Compare Stocks: IFRX, SVRA, FBRX, and CVAC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
FBRX Forte Biosciences	$76.83 0.0%	$43.25	$10.11 ▼ $77.20	$1.07B	2.62	2.27 million shs	490,179 shs
IFRX InflaRx	$2.04 +1.5%	$1.89	$0.80 ▼ $2.95	$296.06M	2.48	920,675 shs	1.47 million shs
SVRA Savara	$5.38 +2.1%	$5.65	$2.92 ▼ $7.01	$1.08B	0.29	1.68 million shs	1.65 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-15.27%
FBRX Forte Biosciences	-0.04%	+0.05%	+74.02%	+232.45%	+626.87%
IFRX InflaRx	+1.49%	+10.87%	+0.99%	-17.41%	+150.00%
SVRA Savara	+2.09%	-7.72%	-7.40%	+6.96%	+99.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
FBRX Forte Biosciences	$76.83 0.0%	$43.25	$10.11 ▼ $77.20	$1.07B	2.62	2.27 million shs	490,179 shs
IFRX InflaRx	$2.04 +1.5%	$1.89	$0.80 ▼ $2.95	$296.06M	2.48	920,675 shs	1.47 million shs
SVRA Savara	$5.38 +2.1%	$5.65	$2.92 ▼ $7.01	$1.08B	0.29	1.68 million shs	1.65 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-15.27%
FBRX Forte Biosciences	-0.04%	+0.05%	+74.02%	+232.45%	+626.87%
IFRX InflaRx	+1.49%	+10.87%	+0.99%	-17.41%	+150.00%
SVRA Savara	+2.09%	-7.72%	-7.40%	+6.96%	+99.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	1.00	Sell	N/A	N/A
FBRX Forte Biosciences	2.14	Hold	$72.50	-5.64% Downside
IFRX InflaRx	2.88	Moderate Buy	$7.33	259.48% Upside
SVRA Savara	2.88	Moderate Buy	$10.14	88.53% Upside

Current Analyst Ratings Breakdown

Latest IFRX, SVRA, FBRX, and CVAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
7/28/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$74.00 ➝ $77.00
7/27/2026	FBRX Forte Biosciences	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$77.00
7/27/2026	FBRX Forte Biosciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/27/2026	FBRX Forte Biosciences	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/27/2026	FBRX Forte Biosciences	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/27/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/21/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
7/21/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
7/17/2026	SVRA Savara	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$13.24 per share	N/A
IFRX InflaRx	-$10.10K	-29,747.32	N/A	N/A	$1.15 per share	1.77
SVRA Savara	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
FBRX Forte Biosciences	-$69.38M	-$4.65	N/A	N/A	N/A	N/A	-94.82%	-77.68%	N/A
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	N/A
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	N/A

Latest IFRX, SVRA, FBRX, and CVAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	FBRX Forte Biosciences	-$0.9950	-$0.97	+$0.0250	-$0.97	N/A	N/A
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/6/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.03	3.70	3.69
FBRX Forte Biosciences	N/A	10.01	2.75
IFRX InflaRx	N/A	8.22	8.22
SVRA Savara	0.21	10.13	13.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
FBRX Forte Biosciences	77.63%
IFRX InflaRx	42.39%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
FBRX Forte Biosciences	4.40%
IFRX InflaRx	16.30%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
FBRX Forte Biosciences	5	13.89 million	13.28 million	Optionable
IFRX InflaRx	60	147.29 million	123.28 million	Optionable
SVRA Savara	20	205.46 million	194.57 million	Optionable

IFRX, SVRA, FBRX, and CVAC Headlines

Recent News About These Companies

Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA

August 15 at 6:39 AM | marketbeat.com

What is HC Wainwright's Estimate for Savara FY2029 Earnings?

August 15 at 2:28 AM | americanbankingnews.com

Savara (NASDAQ:SVRA) Lowered to Sell Rating by Wall Street Zen

August 15 at 1:55 AM | americanbankingnews.com

Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

August 15 at 1:53 AM | marketbeat.com

HC Wainwright Brokers Lower Earnings Estimates for Savara

August 14 at 8:12 AM | marketbeat.com

Savara (NASDAQ:SVRA) Stock Price Down 5.4% - What's Next?

August 13 at 1:59 PM | marketbeat.com

HC Wainwright Has Pessimistic View of Savara FY2029 Earnings

August 13 at 7:56 AM | marketbeat.com

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | caledonianrecord.comC

Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

August 11, 2026 | marketbeat.com

Savara (SVRA) to Post Earnings on Wednesday

August 11, 2026 | americanbankingnews.com

Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC

August 8, 2026 | marketbeat.com

Savara (SVRA) to Announce Quarterly Earnings on Wednesday

August 5, 2026 | marketbeat.com

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

August 5, 2026 | seekingalpha.com

Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA

August 2, 2026 | marketbeat.com

Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 30, 2026 | marketbeat.com

Savara Inc. $SVRA Shares Bought by Eversept Partners LP

July 28, 2026 | marketbeat.com

Orbimed Advisors LLC Acquires Shares of 635,000 Savara Inc. $SVRA

July 27, 2026 | marketbeat.com

Savara Inc. $SVRA Stock Position Boosted by Spruce Street Capital LP

July 25, 2026 | marketbeat.com

Affinity Asset Advisors LLC Decreases Stock Holdings in Savara Inc. $SVRA

July 25, 2026 | marketbeat.com

Savara (SVRA) Gets a Buy from Piper Sandler

July 24, 2026 | theglobeandmail.com

Savara (NASDAQ:SVRA) Sees Unusually-High Trading Volume - Should You Buy?

July 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, SVRA, FBRX, and CVAC Company Descriptions

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 08/14/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Forte Biosciences NASDAQ:FBRX

$76.83 -0.03 (-0.04%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$76.85 +0.02 (+0.03%)

As of 08/14/2026 07:34 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

InflaRx NASDAQ:IFRX

$2.04 +0.03 (+1.49%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.02 -0.02 (-0.98%)

As of 08/14/2026 07:34 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Savara NASDAQ:SVRA

$5.38 +0.11 (+2.09%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$5.38 0.00 (-0.09%)

As of 08/14/2026 07:34 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IFRX, SVRA, FBRX, and CVAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IFRX, SVRA, FBRX, and CVAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IFRX, SVRA, FBRX, and CVAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, SVRA, FBRX, and CVAC Company Descriptions

CureVac NASDAQ:CVAC

Forte Biosciences NASDAQ:FBRX

InflaRx NASDAQ:IFRX

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IFRX, SVRA, FBRX, and CVAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IFRX, SVRA, FBRX, and CVAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IFRX, SVRA, FBRX, and CVAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, SVRA, FBRX, and CVAC Company Descriptions

CureVac NASDAQ:CVAC

Forte Biosciences NASDAQ:FBRX

InflaRx NASDAQ:IFRX

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools